← Back to Patent Explorer
US4110437A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of treating cancerous cachexia in humans with hydrazine sulfate

Assignee: Individual
•
Filing: 1977-02-03
•
Granted: 1978-08-29
•
Expires: 1997-02-03
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Hydrazine sulfate alone or formulated with liquid or solid carriers will retard and reduce cancerous cachexia even in the absence of tumor reduction when administered to humans either orally or parenterally.

Inventors

  • 👤 Joseph Gold

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 19:08
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 43 words
A method of retarding and reducing cancerous cachexia in a human so afflicted which comprises internally administering to said human hydrazine sulfate in an effective dosage sufficient to retard and reduce the cachexia and continuing its use in the absence of tumor reduction.
Claim 2
Independent Claim 43 words
A method of retarding and reducing cancerous cachexia in a human so afflicted which comprises internally administering to said human hydrazine sulfate in an effective dosage sufficient to retard and reduce the cachexia and continuing its use in the absence of tumor reduction.
Claim 3
Dependent Claim 17 words
A method as in claim 1 in which the hydrazine sulfate is administered orally in dosage form.
Claim 4
Dependent Claim 15 words
A method as in claim 2 in which the dosage form is a gelatin capsule.
Claim 5
Dependent Claim 14 words
A method as in claim 1 in which the hydrazine sulfate is administered parenterally.
Claim 6
Dependent Claim 22 words
A method as in claim 1 in which the dosage of hydrazine sulfate is 2 to 5 mg/kg of body weight daily.
Claim 7
Dependent Claim 43 words
A method as in claim 1 in which the hydrazine sulfate is administered in a daily regimen of one 60 milligram capsule for 3 days, then two 60 milligram capsules for the next 3 days and three 60 milligram capsules each day thereafter.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-08-28 1982-02-27 1982-08-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-08-28 1986-02-27 1986-08-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-08-28 1990-02-27 1990-08-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag